Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Arvinas Holding Company ( (ARVN) ) has provided an announcement.
Arvinas announced updated guidance for its Phase 3 clinical trials involving vepdegestrant, a PROTAC ER degrader co-developed with Pfizer, targeting ER+/HER2- breast cancer. The company plans to present data from multiple clinical trials and initiate new trials in 2025, marking significant development milestones and potential value for patients and stakeholders.
More about Arvinas Holding Company
Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform to treat debilitating and life-threatening diseases. The company is involved in clinical programs targeting estrogen receptor-positive breast cancer, B-cell lymphoma, and neurodegenerative disorders.
YTD Price Performance: 4.92%
Average Trading Volume: 770,544
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.36B
For a thorough assessment of ARVN stock, go to TipRanks’ Stock Analysis page.